 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Life Tech Continues to Gather Evidence Backing NSCLC Dx Pervenio, As Commercialization Progresses
February 06, 2013
Life Tech Continues to Gather Evidence Backing NSCLC Dx Pervenio, As Commercialization Progresses
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Following CLIA Lab Buy, Life Tech Jumps into MDx Space with Purchase of Pinpoint, Lung Cancer Dx
July 25, 2012 / Pharmacogenomics Reporter - Life Technologies Acquires Lung Cancer Test Developer Pinpoint Genomics
July 25, 2012 / GenomeWeb Daily News - Insight Genetics Wins $1.5M Grant to Begin Clinical Testing for ALK Mutation CDx on Qiagen Platform
October 11, 2012 / PCR Insider - Dx Focus: Life Tech Pervenio Lung RS; BD Max CRE Test; Gynecor Offers Roche Cobas HPV Test
September 27, 2012 / PCR Insider - Life Tech to Market Dx Version of QuantStudio Platform; Developing Assays with Quidel
July 26, 2012 / PCR Insider